Company

Nammi Therapeutics, Inc.

Nammi Therapeutics develops immunotherapies designed to activate the immune system at tumor sites.

About

Nammi Therapeutics develops cancer immunotherapies designed to activate the immune system at tumor sites. Its pipeline includes Masked ImmunoCytokines and Nammisomes, lipid nanoparticles that deliver immune modulators. Founded by CEO David Stover, the company is based in Los Angeles, US. It raised USD 28.39 mn in Series B funding in March 2023.

1Funding rounds

1Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in